•
Jun 30, 2024

Glaukos Q2 2024 Earnings Report

Glaukos' second quarter results reflected successful global execution and growing momentum.

Key Takeaways

Glaukos Corporation reported record net sales of $95.7 million in Q2 2024, a 19% increase year-over-year. The company raised its 2024 net sales guidance to $370 million to $376 million.

Record net sales of $95.7 million in Q2 2024 increased 19% year-over-year on a reported basis and 20% year-over-year on a constant currency basis.

Glaucoma record net sales of $75.9 million in Q2 2024 increased 23% year-over-year.

Corneal Health net sales of $19.8 million in Q2 2024 increased 7% year-over-year.

Gross margin of approximately 76% and non-GAAP gross margin of approximately 82% in Q2 2024.

Total Revenue
$95.7M
Previous year: $80.4M
+19.0%
EPS
-$0.52
Previous year: -$0.55
-5.5%
Gross margin
76%
Previous year: 75%
+1.3%
Non-GAAP gross margin
82%
Previous year: 82%
+0.0%
SG&A expenses
$66.2M
Previous year: $53.1M
+24.7%
Gross Profit
$73.1M
Previous year: $60.3M
+21.3%
Cash and Equivalents
$68.1M
Previous year: $94.8M
-28.2%
Free Cash Flow
-$20.5M
Previous year: -$13.9M
+47.3%
Total Assets
$920M
Previous year: $957M
-3.9%

Glaukos

Glaukos

Glaukos Revenue by Segment

Forward Guidance

The company expects 2024 net sales to be in the range of $370 million to $376 million based on the latest foreign currency exchange rates.

Revenue & Expenses

Visualization of income flow from segment revenue to net income